[DOI] [PubMed] [Google Scholar] 121.Hsieh M.J., Lee C.H., Chueh H.Y., Chang G.J., Huang H.Y., Lin Y., Pang J.S
For example, a 2011 study in rats found that the peptide successfully healed various lesions and promoted healthy weight gain in models of short-bowel syndrome.14 Additionally, as researchers note in the aforementioned 2016 review on BPC-157 and the gut-brain axis, BPC 157 was successful in the therapy of GI tract, periodontitis, liver and pancreas lesions, and in the healing of various tissues and wounds. Its also written in the review that the peptide acts as a mediator of Roberts cytoprotection, defined as the counteraction of the lesions arising from direct detrimental contact with a noxious agent.7 15 Insider Tip: Though there has been some small-scale positive human research on BPC-157, most of the peptides potential uses are based on the outcomes of animal or cell studies
The split dosing approach maintains more consistent NNMT inhibition throughout the day, potentially enhancing metabolic benefits
Figure AD Step 31: Turn the vial and syringe upside down
It can be combined with BPC 157 for daily intramuscular injection (with tiny insulin needles) or combined with BPC 157 in a tendon or joint injection with Dr
A peptide that modulates VEGFR2 in a cell culture dish, or heals a rat tendon at 10 mcg/kg IP injection, has not been shown to survive oral delivery in a human at 500 mcg and reach musculoskeletal tissue at any meaningful concentration
